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An outbreak of gastrointestinal illness, associated with travel to Egypt, is being investigated. An airplane arrived in Dublin on 1st June 2005, carrying holidaymakers returning from Luxor in Egypt, many of whom were experiencing, or had recently experienced, significant gastrointestinal symptoms. The ill passengers were resident throughout the Republic of Ireland and Northern Ireland and a joint investigation involving public health, environmental health and microbiology professionals was undertaken.
Onset of illness was between 26th and 31st May. Two of the passengers have been diagnosed with Shigella sonnei infection. Further results are awaited. A study to determine the factors contributing to this outbreak is underway, and all passengers are being contacted to determine the extent of illness and to provide advice on hygiene and exclusion from school and work, particularly to those at heightened risk of onward transmission of illness. To date, 71 of 109 passengers interviewed (65%) have reported illness.
The Egyptian authorities were alerted and an alert was also sent through the EU's Early Warning and Response System (EWRS) on 10th June 2005 and through Enter-net (the international surveillance network for human gastrointestinal infections, h t t p : / / w w w. h p a . o r g . u k / h p a / i n t e r / e n t e rnet_menu.htm) on 13th June 2005 to inform EU Member States and Enter-net participants of the situation and to determine if what was being observed in Ireland was part of a larger outbreak.
The tour operators who organised the travel have undertaken a review of the hygiene standards in locations for which they have responsibility in Luxor in order to prevent recurrence. Investigations have indicated that an air scrubber (air polution control device) in a lignin processing plant is the source of the outbreak. The scrubber cleans particles in the air used in the production process by exposing it to a strong counterflow of water. The scrubber operates at 40ºC and expels more than 4 cubic metres of water/hour as aerosol. The tank of the scrubber was routinely cleaned with high-pressure hot water every 3-4 weeks, but no disinfection was used. The pumps and pipes had not been manually cleaned.
In legionellosis outbreaks a risk assessment of air scrubbers regarding conditions facilitating Legionella growth (such as temperature and biofilm formation) should be carried out. The report is intended to provide a feedback mechanism to regulatory bodies and agencies and can be used to assess the effectiveness of control measures.
The trends in zoonoses were similar to those reported in 2000 and 2001. Campylobacteriosis was the most common bacterial zoonotic disease reported followed by salmonellosis and VTEC. Despite the control measures that are in place and extensive education campaigns, the peak incidence of zoonotic infections continues to be reported in the summer months when outdoor cooking is prevalent and consumption of pre-prepared and chilled foods is more common.
Introduction
Prior to 1999 and the introduction of the European Antimicrobial Resistance Surveillance System (EARSS), there was no national surveillance of antimicrobial resistance (AMR) undertaken in Ireland, although some surveillance was carried out locally and regionally. EARSS was initially established and funded under the Directorate General for Health and Consumer Protection (DGSanco) of the European Commission in 1998 and is now partly funded by the Dutch Ministry of Health, Welfare and Sports. At the European level, EARSS is co-ordinated by the Dutch Institute for Public Health and the Environment (RIVM). EARSS has grown over the years and now consists of a network of 30 national surveillance systems, covering over 800 hospitals and over 100 million people. It aims to provide reliable and accurate data on antimicrobial resistance (AMR) on invasive isolates of five key pathogens:
• Staphylococcus aureus (SAU) from blood only
• Streptococcus pneumoniae (SPN) from blood or CSF
• Escherichia coli (ECO) from blood or CSF
• Enterococcus faecalis (EFA) from blood only
• Enterococcus faecium (EFM) from blood only. 
EARSS is co-ordinated in

Methods
EARSS collects routinely generated antimicrobial susceptibility data on "the first invasive isolate per patient per quarter" for each of the above pathogens. Some of the key antibiotics required for each pathogen by the EARSS protocol are as listed in table 1 (see http://www.earss.rivm.nl for the latest protocols). HPSC collects these data nationally on a quarterly basis. The collated national data are submitted to the EARSS Management Team at RIVM.
Results
S. aureus
In 2004, there were 1,323 reports of S. aureus bacteraemia, of which 41.8% were resistant to methicillin (methicillin-resistant S. aureus, MRSA). This represents a slight decrease on the proportions of MRSA observed in the previous two years (table 1).
The mean ages of patients with methicillin-sensitive S. aureus (MSSA) and MRSA bacteraemia were 51 and 67 years, respectively (P < 0.0001). The probability of acquiring MRSA bacteraemia as opposed to MSSA bacteraemia in patients aged 65 years or more was 1.9 times greater than in patients under 65 years (RR, 1.9; 95% confidence interval, 1.71-2.12). There were more isolates from males than females for both MSSA (60% vs 39%, P <0.0001) and No MICs were reported on six isolates (15%), which were termed "non-susceptible" (NS). Fifty five (14.2%) of 388 isolates tested were resistant to erythromycin. In addition, seven PNSP (including LLR, HLR and NS) isolates were resistant to erythromycin. The proportion of PNSP in Ireland has been decreasing over the six years of surveillance of this pathogen (table 1). The proportions of both PNSP and erythromycin-resistant S. pneumoniae in Ireland are at moderate levels compared to other countries reporting to EARSS. The highest proportions of both are observed in Spain and Slovakia.
E. coli
In 2004, there were 1,256 reports of invasive E. coli infection, of which 2.4%, 12.5% and 5.7% were resistant to third generation cephalosporins (3GCs), ciprofloxacin and gentamicin, respectively. Eleven isolates (1.3% of isolates tested) were found to produce extended-spectrum beta-lactamases (ESBLs), enzymes that confer resistance to all beta-lactam antibiotics with the exception of carbapenems. Over the three years that surveillance of this pathogen has been on-going, the proportions of isolates resistant to both ciprofloxacin and gentamicin have increased.
In 2004, there were 61 reports of multi-drug resistant (MDR) E. coli isolates, defined as resistance to three or more of the four antibiotic classes (ampicillin, 3GCs, ciprofloxacin and gentamicin) required by the EARSS protocol. This represents 6% of all isolates compared with 3.7% (33 isolates 
E. faecalis
In 2004, there were 242 reports of E. faecalis bacteraemia, of which 1.4% were resistant to vancomycin (vancomycin-resistant E. faecalis, VREfa) and 42.2% were resistant to high-level gentamicin (HLG). Although the proportion of VREfa in Ireland is low, it is still slightly higher than that reported in most countries.
Resistance to HLG among E. faecalis is common throughout Europe.
E. faecium
In 2004, there were 187 reports of E. faecium bacteraemia, of which 23.2% were resistant to vancomycin (vancomycin-resistant E. faecium, VREfm) and 57.8% were resistant to high-level gentamicin (HLG). The proportion of VREfm has increased over the three years of surveillance of this pathogen (table 1) It is recognised that continued and improved feedback to the laboratories and public health professionals is a vital part of any surveillance system. In addition to the quarterly newsletters and the annual report, both with aggregate national data, each laboratory receives individual feedback with a summary report of its own data for each quarter and the cumulative total for the year. Regional reports are also generated and distributed to the regional SARI (Strategy for the Control of Antimicrobial Resistance in Ireland) committees and to the relevant clinical microbiologists and medical scientists. Reports with calculated rates of infection (using DoHC Acute Public Hospital Activity) are being developed, the purpose of which will be to further inform effective and appropriate infection control measures. When analysing and interpreting such data (both proportions and rates) geographically, it is important to emphasise that there are often fundamental differences between hospitals and regions. Hospitals serve different populations, some are specialist centres and others are tertiary referral centres and each may have different case mixes (types of patients). Building infrastructure, staffing levels and other resources also vary from hospital to hospital and these factors can influence proportions and rates of infection with AMR organisms. It is also important to consider that an AMR organism, such as MRSA, isolated from a patient may in fact have originated in a different hospital or institution (or indeed in the community).
To understand further the epidemiology of AMR organisms, an enhanced surveillance system has been set up and all laboratories with appropriate staff and resources are encouraged to participate. An update on the enhanced surveillance of the EARSS pathogens will be presented in an upcoming edition of Epi-Insight. States are required to ensure that they develop and implement plans of action to ensure that these core capacities are present and functioning throughout their territory. These core capacities must be available on a 24-hour basis.
The above information and more detailed information on the new regulations is available on the WHO website at www.who.int/mediacentre/news/releases/2005/pr_wha03/en/ind ex.html
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